Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

BACKGROUND: The majority of patients with hemophilia A with inhibitors who undergo immune tolerance induction (ITI) achieve successful tolerance and transition to factor VIII (FVIII) prophylaxis. A portion of these patients have switched to emicizumab for bleeding prevention. However, the risk of in...

Descripción completa

Detalles Bibliográficos
Autores principales: Batsuli, Glaivy, Greene, Amanda, Meeks, Shannon L., Sidonio, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles ‐ Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938619/
https://www.ncbi.nlm.nih.gov/pubmed/33733033
http://dx.doi.org/10.1002/rth2.12475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938619/
https://www.ncbi.nlm.nih.gov/pubmed/33733033
http://dx.doi.org/10.1002/rth2.12475

Ejemplares similares